Salem Partners

Fabric is a cloud platform that enables customers to manage editorial, technical, and other metadata for television shows, movies, documentaries, games, and other media. With Fabric, you can easily connect your catalogue to new platforms, transform internal data processes, and deliver dramatically improved viewer and user experiences.

Form Bio is a biotechnology company that focuses on enhancing scientific discovery by addressing the challenges related to data, computation, and technical aspects in life sciences. The company offers a comprehensive platform that integrates the entire discovery process, featuring intuitive software applications designed for workflows, data management, collaboration, and data visualization. This platform is aimed at lab directors, biotech firms, pharmaceutical companies, and academic institutions, providing them with the tools necessary to efficiently manage and utilize the growing volume of data and computing power in their research endeavors. By fostering an open and adaptable collaborative environment, Form Bio enables scientists to streamline their workflows and improve their overall productivity.

OncoNano Medicine, Inc. is a biotechnology company based in Southlake, Texas, founded in 2014. The company specializes in developing pH-activated compounds and nanotechnology-enabled fluorescent probes aimed at improving cancer surgery outcomes. Its flagship program, ONM-100, targets tumor acidosis to differentiate cancerous tissue from healthy tissue, allowing surgeons to visualize tumors more accurately during procedures. By exploiting the variability of pH in disease, OncoNano Medicine's innovative approach enhances the precision of tumor excision and aids in the detection and treatment of diseased tissue. This technology not only assists in intraoperative cases but also supports post-surgery evaluations, making it a valuable tool in cancer care.

Fabric is a cloud platform that enables customers to manage editorial, technical, and other metadata for television shows, movies, documentaries, games, and other media. With Fabric, you can easily connect your catalogue to new platforms, transform internal data processes, and deliver dramatically improved viewer and user experiences.

Levels Beyond, Inc. is a software company based in Denver, Colorado, specializing in media management and workflow solutions. The company develops a content inventory platform known as Reach Engine, which facilitates the organization, production, and sharing of digital media for production teams and media manufacturers. This platform enables users to create, curate, and distribute video content efficiently across various tools while integrating cloud services to enhance media workflows. Levels Beyond also offers a content management system that supports publishing across multiple platforms, catering to sectors such as media and entertainment, sports and live events, marketing, and new media distribution. Founded in 2000, the company has established a strategic partnership with Verizon Digital Media Services to further enhance its offerings.

OncoNano Medicine, Inc. is a biotechnology company based in Southlake, Texas, founded in 2014. The company specializes in developing pH-activated compounds and nanotechnology-enabled fluorescent probes aimed at improving cancer surgery outcomes. Its flagship program, ONM-100, targets tumor acidosis to differentiate cancerous tissue from healthy tissue, allowing surgeons to visualize tumors more accurately during procedures. By exploiting the variability of pH in disease, OncoNano Medicine's innovative approach enhances the precision of tumor excision and aids in the detection and treatment of diseased tissue. This technology not only assists in intraoperative cases but also supports post-surgery evaluations, making it a valuable tool in cancer care.

RightsLine is a global rights and royalties management software company that specializes in providing a comprehensive platform for intellectual property (IP) owners to effectively manage and monetize their content throughout its lifecycle. The company's innovative technology tools are designed to serve a diverse range of industries, including media and entertainment, gaming, publishing, consumer products, life sciences, and high tech. RightsLine offers features such as real-time availability, pipeline management, contract visibility, and inventory management, enabling finance, legal, operations, and strategy teams to gain a complete understanding of their content's rights, royalties, contracts, and sales opportunities. This robust SaaS solution simplifies complex rights management processes, enhancing the ability of clients to maximize the value of their IP assets.

Lucid Sight, Inc. is a computer software company based in Los Angeles, California, that specializes in the design and development of virtual reality games and software applications. Founded in 2015, the company focuses on creating immersive entertainment experiences using blockchain, augmented reality, and virtual reality technologies. Lucid Sight develops multiplayer adventure and sports games, aiming to provide engaging interfaces for gamers. Additionally, the company offers tools and plug-ins for virtual reality developers and innovative monetization and marketing platforms for brands and game developers. Through its catalog, Lucid Sight serves a diverse clientele, including developers and advertisers, by leveraging emerging technologies to enhance gaming and marketing experiences.

RightsLine is a global rights and royalties management software company that specializes in providing a comprehensive platform for intellectual property (IP) owners to effectively manage and monetize their content throughout its lifecycle. The company's innovative technology tools are designed to serve a diverse range of industries, including media and entertainment, gaming, publishing, consumer products, life sciences, and high tech. RightsLine offers features such as real-time availability, pipeline management, contract visibility, and inventory management, enabling finance, legal, operations, and strategy teams to gain a complete understanding of their content's rights, royalties, contracts, and sales opportunities. This robust SaaS solution simplifies complex rights management processes, enhancing the ability of clients to maximize the value of their IP assets.

AsclepiX Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for retinal diseases and certain cancers. The company specializes in designing short biomimetic peptides that target angiogenesis and lymphangiogenesis, utilizing advanced bioinformatics and systems biology approaches. Its lead product candidates, including AXT107, AXT201, AXT301, and AXT501, are aimed at addressing conditions such as diabetic macular edema, age-related macular degeneration, and macular edema from retinal vein occlusion, all of which are significant causes of blindness in the western world. Additionally, AXT201, AXT301, and AXT501 are in early development stages for treating various solid tumors. AsclepiX Therapeutics employs cutting-edge biomaterials and drug delivery systems, including biodegradable nano and microparticles, to enhance the therapeutic efficacy of its peptide-based treatments. Incorporated in 2011 and headquartered in Baltimore, Maryland, the company is leveraging its platform technology to advance solutions in both ophthalmology and oncology.

OncoNano Medicine, Inc. is a biotechnology company based in Southlake, Texas, founded in 2014. The company specializes in developing pH-activated compounds and nanotechnology-enabled fluorescent probes aimed at improving cancer surgery outcomes. Its flagship program, ONM-100, targets tumor acidosis to differentiate cancerous tissue from healthy tissue, allowing surgeons to visualize tumors more accurately during procedures. By exploiting the variability of pH in disease, OncoNano Medicine's innovative approach enhances the precision of tumor excision and aids in the detection and treatment of diseased tissue. This technology not only assists in intraoperative cases but also supports post-surgery evaluations, making it a valuable tool in cancer care.

Sebacia, Inc. is a medical device company based in Duluth, Georgia, specializing in light-based therapies for dermatological conditions, particularly acne. Founded in 2008, Sebacia aims to provide innovative alternatives to traditional topical and systemic drugs used to treat acne. The company's technology utilizes a formulation of gold microparticles that are applied to the skin and subsequently treated with a standard dermatology laser. This method selectively targets the skin structures involved in acne, addressing unmet needs in dermatology. Sebacia's patented technology was initially developed at Rice University and further advanced in collaboration with researchers at the Wellman Center of Photomedicine at Massachusetts General Hospital.

Lucid Sight, Inc. is a computer software company based in Los Angeles, California, that specializes in the design and development of virtual reality games and software applications. Founded in 2015, the company focuses on creating immersive entertainment experiences using blockchain, augmented reality, and virtual reality technologies. Lucid Sight develops multiplayer adventure and sports games, aiming to provide engaging interfaces for gamers. Additionally, the company offers tools and plug-ins for virtual reality developers and innovative monetization and marketing platforms for brands and game developers. Through its catalog, Lucid Sight serves a diverse clientele, including developers and advertisers, by leveraging emerging technologies to enhance gaming and marketing experiences.

Femasys Inc. is a biomedical company based in Suwanee, Georgia, dedicated to advancing women's healthcare through innovative medical devices. Founded in 2004, the company specializes in non-surgical solutions for female sterilization, infertility diagnosis, and cervical cancer screening. Its lead products include FemBloc, the first non-surgical method for permanent birth control, and FemaSeed, a directed sperm delivery system designed to enhance infertility treatment. Additionally, Femasys markets FemVue, an ultrasound-based product for assessing fallopian tube health, as a key focus of its commercial efforts. The company aims to provide minimally invasive technologies that can be utilized in office settings, thereby improving patient care and health economics in areas that are often underserved in women's health.

ZS Pharma, Inc. is a biopharmaceutical company based in Coppell, Texas, specializing in the development and commercialization of non-absorbed drugs aimed at treating renal, cardiovascular, liver, and metabolic diseases. Founded in 2008, the company focuses on creating highly selective ion-trap therapies using its proprietary zirconium silicate technology, which allows for the reduction of toxic electrolyte levels while maintaining overall electrolyte balance. Its lead product, ZS-9, is an insoluble, non-absorbed zirconium silicate currently in Phase III clinical trials for the treatment of hyperkalemia, a serious condition characterized by elevated potassium levels in the blood, often affecting patients with chronic kidney disease, hypertension, diabetes, or heart failure. As of December 2015, ZS Pharma operates as a subsidiary of Zeneca, Inc.

ZS Pharma, Inc. is a biopharmaceutical company based in Coppell, Texas, specializing in the development and commercialization of non-absorbed drugs aimed at treating renal, cardiovascular, liver, and metabolic diseases. Founded in 2008, the company focuses on creating highly selective ion-trap therapies using its proprietary zirconium silicate technology, which allows for the reduction of toxic electrolyte levels while maintaining overall electrolyte balance. Its lead product, ZS-9, is an insoluble, non-absorbed zirconium silicate currently in Phase III clinical trials for the treatment of hyperkalemia, a serious condition characterized by elevated potassium levels in the blood, often affecting patients with chronic kidney disease, hypertension, diabetes, or heart failure. As of December 2015, ZS Pharma operates as a subsidiary of Zeneca, Inc.